Halo Biosciences
Transforming the treatment of
inflammatory and fibrotic diseases
Halo Biosciences
Transforming the treatment of
inflammatory and fibrotic diseases
Our Mission
Halo is a clinical-stage biotechnology company creating first-in-class, disease-modifying therapies for the treatment of inflammatory and fibrotic diseases. Our first indication is pulmonary hypertension and interstitial lung disease.
Our Science
The ECM in Disease
We are building a differentiated pipeline based on novel insights into how extracellular matrix (ECM) dysregulation drives disease
Our primary target is Hyaluronan (HA), a key component of the ECM
Alterations to HA is associated with a variety of conditions characterized by inflammation and fibrosis, including pulmonary hypertension, pulmonary fibrosis, and liver fibrosis
Our Pipeline
Novel target for inflammation and fibrosis
Our pipeline is focused on delivering first- and best-in-class hyaluronan remodeling agents that act on novel targets with a differentiated mechanism of action
Our lead indication is pulmonary hypertension and interstitial lung disease, a set of progressive and fatal diseases characterized by inflammation, fibrosis, and vascular remodeling of the lung